Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.

Summary: Ovarian clear cell adenocarcinoma (OCCA) is a difficult-to-treat form of ovarian cancer. Doctors have been searching for better ways to predict which patients will respond best to chemotherapy. This study looked at a specific protein called "E-cadherin," which acts like a glue holding cells together.

Researchers analyzed tumor samples from 61 patients. They found that patients whose tumors had high levels of E-cadherin lived significantly longer than those with low levels. Furthermore, the study discovered that a specific chemotherapy drug, Paclitaxel, was highly effective—but primarily for those patients with the "sticky" E-cadherin protein.

The Takeaway: Testing for E-cadherin could help doctors identify which ovarian cancer patients will benefit most from Paclitaxel chemotherapy, potentially saving lives by tailoring treatment to the tumor's biology.